Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

About this update from Cascade Copper Corp.

[{"type":"text","content":"\n\n\n\nSEATTLE, May 18 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today\nannounced upcoming presentations at the American Society of Clinical Oncology\n(ASCO) Annual Meeting being held May 29-June 2, 2009 in Orlando, Florida.\nAbstracts related to our product candidates Stimuvax(R), PX-866 and PX-12 are\nnow available to the public online at the ASCO Web site,\nwww.abstract.asco.org.\n\n\nAbstracts include:\n\n- "Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients\n (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)"\n\n - Abstract No: 3055 Poster session: Developmental Therapeutics:\n Immunotherapy - Saturday May 30, 8:00 AM to 12:00 PM, Level 2,\n West Hall C\n\n- "Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K)\n inhibitor"\n\n - Abstract No: 3542 Poster session: Developmental Therapeutics:\n Molecular Therapeutics - Saturday May 30, 8:00 AM to 12:00 PM\n Level 2, West Hall C\n\n- "Results from phase Ib studies of PX-12, a thioredoxin inhibitor in\n patients with advanced solid malignancies"\n\n - Abstract No. 2571, Poster Session: Developmental Therapeutics:\n Cytotoxic Chemotherapy - Saturday May 30, 8:00 AM to 12:00 PM,\n Level 2, West Hall C\n\n\nAbout Oncothyreon\n\n\nOncothyreon is a biotechnology company specializing in the development of\ninnovative therapeutic products for the treatment of cancer. Oncothyreon's\ngoal is to develop and commercialize novel synthetic vaccines and targeted\nsmall molecules that have the potential to improve the lives and outcomes of\ncancer patients. For more information, visit www.oncothyreon.com.\n\n\nForward-Looking Statements\n\n\nIn order to provide Oncothyreon's investors with an understanding of its\ncurrent intentions and future prospects, this release contains statements that\nare forward-looking, including statements related to future preclinical and\nclinical development plans for our product candidates. These forward-looking\nstatements represent Oncothyreon's intentions, plans, expectations and beliefs\nand are based on its management's experience and assessment of historical and\nfuture trends and the application of key assumptions relating to future events\nand circumstances.\n\n\nForward-looking statements involve risks and uncertainties, including\nrisks and uncertainties related to Oncothyreo...

More updates from Cascade Copper Corp.